How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?
AbbVie Inc. has issued earnings guidance for 2015 that calls for 30% growth.
1 Big Loser in the Slugfest Between AbbVie and Gilead Sciences
It's a heavyweight hep-C bout between AbbVie and Gilead Sciences. Who is losing?
Which Big Biotech Will Soar in 2015?
Motley Fool contributors think that Gilead Sciences, Biogen Idec, and Celgene Corp could be top performers in 2015.